{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:01Z","timestamp":1791563041351,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi S.P.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Given the availability and efficacy of the mobilizing agent plerixafor in augmenting hematopoietic progenitor cell mobilization with granulocyte colony-stimulating factor (G-CSF), there is a strong case for comparing the cost-effectiveness of mobilization with G-CSF\u2009+\u2009cyclophosphamide versus G-CSF alone. This study investigated the cost and effectiveness (i.e., successful 4 million-CD34<jats:sup>+<\/jats:sup>collection) of G-CSF alone versus high-dose cyclophosphamide (4\u2009g\/m<jats:sup>2<\/jats:sup>) + G-CSF mobilization (\u00b1 on-demand plerixafor) in patients with multiple myeloma (MM) eligible for autograft in Italy. A decision tree-supported cost-effectiveness analysis (CEA) model in MM patients was developed from the societal perspective. The CEA model compared G-CSF alone with cyclophosphamide 4\u2009g\/m<jats:sup>2<\/jats:sup>\u2009+\u2009G-CSF (\u00b1\u2009on-demand plerixafor) and was populated with demographic, healthcare and non-healthcare resource utilization data collected from a questionnaire administered to six Italian oncohematologists. Costs were expressed in Euro (\u20ac) 2019. The CEA model showed that G-CSF alone was strongly dominant versus cyclophosphamide + G-CSF (\u2009\u00b1\u2009on-demand plerixafor), with incremental savings of \u20ac1198.59 and an incremental probability of a successful 4 million-CD34<jats:sup>+<\/jats:sup>apheresis (+0.052). Sensitivity analyses confirmed the robustness of the base-case results. In conclusion, chemotherapy-free mobilization (\u00b1 on-demand plerixafor) is a \u201cgood value for money\u201d option for MM patients eligible for autograft.<\/jats:p>","DOI":"10.1038\/s41409-021-01251-8","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T17:02:57Z","timestamp":1616432577000},"page":"1876-1887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1 plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4795-1834","authenticated-orcid":false,"given":"Carlo","family":"Lazzaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-7167","authenticated-orcid":false,"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0279-5623","authenticated-orcid":false,"given":"Daniele","family":"Laszlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4414","authenticated-orcid":false,"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pierelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","volume":"20","author":"A Alegre","year":"1997","unstructured":"Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transpl. 1997;20:211\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1700867. e-pub ahead of print 1997\/08\/01","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","volume":"98","author":"H Goldschmidt","year":"1997","unstructured":"Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol. 1997;98:736\u201344. https:\/\/doi.org\/10.1046\/j.1365-2141.1997.2783095.x. e-pub ahead of print 1997\/10\/23","journal-title":"Br J Haematol"},{"key":"1251_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:865\u201372. https:\/\/doi.org\/10.1038\/bmt.2014.39. e-pub ahead of print 2014\/04\/02","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000070967","volume":"109","author":"MT Petrucci","year":"2003","unstructured":"Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, et al. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Acta Haematol. 2003;109:184\u20138. https:\/\/doi.org\/10.1159\/000070967. e-pub ahead of print 2003\/07\/11","journal-title":"Acta Haematol"},{"key":"1251_CR5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","volume":"18","author":"M Hamadani","year":"2012","unstructured":"Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transpl. 2012;18:1128\u201335. https:\/\/doi.org\/10.1016\/j.bbmt.2012.01.005. e-pub ahead of print 2012\/01\/18","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/14653240701452800","volume":"9","author":"DK Hiwase","year":"2007","unstructured":"Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy. 2007;9:539\u201347. https:\/\/doi.org\/10.1080\/14653240701452800. e-pub ahead of print 2007\/09\/21","journal-title":"Cytotherapy"},{"key":"1251_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1703840","volume":"31","author":"E Jantunen","year":"2003","unstructured":"Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transpl. 2003;31:347\u201351. https:\/\/doi.org\/10.1038\/sj.bmt.1703840. e-pub ahead of print 2003\/03\/14","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR8","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","volume":"6","author":"D Dingli","year":"2006","unstructured":"Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma. 2006;6:384\u20138. https:\/\/doi.org\/10.3816\/CLM.2006.n.014. e-pub ahead of print 2006\/04\/28","journal-title":"Clin Lymphoma Myeloma"},{"key":"1251_CR9","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","volume":"24","author":"A Oyekunle","year":"2018","unstructured":"Oyekunle A, Shumilov E, Kostrewa P, Burchert A, Trumper L, Wuchter P, et al. Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens. Biol Blood Marrow Transpl. 2018;24:276\u201381. https:\/\/doi.org\/10.1016\/j.bbmt.2017.10.008. e-pub ahead of print 2017\/10\/19","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bmt.2015.190","volume":"50","author":"GL Uy","year":"2015","unstructured":"Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transpl. 2015;50:1513\u20138. https:\/\/doi.org\/10.1038\/bmt.2015.190. e-pub ahead of print 2015\/08\/25","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.transci.2012.03.004","volume":"47","author":"G Andreola","year":"2012","unstructured":"Andreola G, Vanazzi A, Radice D, Babic A, Rabascio C, Negri M, et al. Who should be really considered as a poor mobilizer in the plerixafor era? Transfus Apher Sci. 2012;47:27\u201332. https:\/\/doi.org\/10.1016\/j.transci.2012.03.004. e-pub ahead of print 2012\/04\/07","journal-title":"Transfus Apher Sci"},{"key":"1251_CR12","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113:5720\u20136. https:\/\/doi.org\/10.1182\/blood-2008-08-174946. e-pub ahead of print 2009\/04\/14","journal-title":"Blood"},{"key":"1251_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/trf.12265","volume":"54","author":"F Lanza","year":"2014","unstructured":"Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion. 2014;54:331\u20139. https:\/\/doi.org\/10.1111\/trf.12265. e-pub ahead of print 2013\/06\/21","journal-title":"Transfusion"},{"key":"1251_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1517\/14712598.2015.971750","volume":"15","author":"F Lanza","year":"2015","unstructured":"Lanza F, Gardellini A, Laszlo D, Martino M. Plerixafor: what we still have to learn. Expert Opin Biol Ther. 2015;15:143\u20137. https:\/\/doi.org\/10.1517\/14712598.2015.971750. e-pub ahead of print 2014\/10\/16","journal-title":"Expert Opin Biol Ther"},{"key":"1251_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/bmt.2014.196","volume":"50","author":"I Sanchez-Ortega","year":"2015","unstructured":"Sanchez-Ortega I, Querol S, Encuentra M, Ortega S, Serra A, Sanchez-Villegas JM, et al. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization. Bone Marrow Transpl. 2015;50:34\u201339. https:\/\/doi.org\/10.1038\/bmt.2014.196. e-pub ahead of print 2014\/09\/16","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR16","doi-asserted-by":"publisher","unstructured":"Clark RE, Bell J, Clark JO, Braithwaite B, Vithanarachchi U, McGinnity N, et al. Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. Blood Cancer J 2014; 4: e255. e-pub ahead of print 2014\/11\/02; https:\/\/doi.org\/10.1038\/bcj.2014.79","DOI":"10.1038\/bcj.2014.79"},{"key":"1251_CR17","doi-asserted-by":"publisher","unstructured":"Abdel-Rahman F, Tuffaha HW, Sharma S, Jazar HA, Hussein N, Saad A, et al. GCSF with or without chemotherapy compared to plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis. J Oncol Pharm Pract 2014; 20: 130-6. e-pub ahead of print 2013\/05\/17; https:\/\/doi.org\/10.1177\/1078155213484785.","DOI":"10.1177\/1078155213484785"},{"key":"1251_CR18","doi-asserted-by":"publisher","unstructured":"Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013; 48: 1279-84. e-pub ahead of print 2013\/04\/16; https:\/\/doi.org\/10.1038\/bmt.2013.52.","DOI":"10.1038\/bmt.2013.52"},{"key":"1251_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/jca.21280","volume":"28","author":"L Chaudhary","year":"2013","unstructured":"Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, et al. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. J Clin Apher. 2013;28:359\u201367. https:\/\/doi.org\/10.1002\/jca.21280. e-pub ahead of print 2013\/06\/15","journal-title":"J Clin Apher"},{"key":"1251_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jca.21433","volume":"31","author":"AP Martin","year":"2016","unstructured":"Martin AP, Richards S, Haycox A, Houten R, McLeod C, Braithwaite B, et al. Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. J Clin Apher. 2016;31:434\u201342. https:\/\/doi.org\/10.1002\/jca.21433. e-pub ahead of print 2015\/09\/30","journal-title":"J Clin Apher"},{"key":"1251_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","volume":"19","author":"IN Micallef","year":"2013","unstructured":"Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transpl. 2013;19:87\u201393. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.010. e-pub ahead of print 2012\/08\/28","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/10428194.2017.1324161","volume":"59","author":"G Milone","year":"2018","unstructured":"Milone G, Martino M, Leotta S, Spadaro A, Zammit V, Cupri A, et al. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. Leuk Lymphoma. 2018;59:42\u201348. https:\/\/doi.org\/10.1080\/10428194.2017.1324161. e-pub ahead of print 2017\/06\/03","journal-title":"Leuk Lymphoma"},{"key":"1251_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/jca.21290","volume":"28","author":"A Tichop\u00e1d","year":"2013","unstructured":"Tichop\u00e1d A, Vitova V, Koristek Z, Lysak D. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients. J Clin Apher. 2013;28:395\u2013403. https:\/\/doi.org\/10.1002\/jca.21290. e-pub ahead of print 2013\/08\/08","journal-title":"J Clin Apher"},{"key":"1251_CR24","unstructured":"Lohr SL Sampling: design and analysis, 2nd edn Brooks\/Cole: Boston, USA, 2010."},{"key":"1251_CR25","unstructured":"Drummond MF, Schulper MJ, Claxton K, Stoddart GL, Torrance GW Methods for the economic evaluation of health care programmes, 4th edn Oxford University Press: Oxford, UK, 2015."},{"key":"1251_CR26","doi-asserted-by":"crossref","unstructured":"Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE (eds). Cost-effectiveness in health and medicine, 2nd edn Oxford University Press: New York, USA, 2016.","DOI":"10.1093\/acprof:oso\/9780190492939.001.0001"},{"key":"1251_CR27","doi-asserted-by":"crossref","unstructured":"Briggs A, Schulper M, Claxton K Decision modelling for health economic evaluation, Oxford University Press: Oxford, UK, 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"1251_CR28","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak. 1993;13:322\u201338. https:\/\/doi.org\/10.1177\/0272989X9301300409. e-pub ahead of print 1993\/10\/01","journal-title":"Med Decis Mak"},{"key":"1251_CR29","unstructured":"Standing Conference on the Relations between the State, the Regions and the Autonomous Provinces of Trento and Bolzano. National agreement on tariffs for inter-regional mobility of patients. Version in force for 2014-5 and 2016. Rome, 2 February 2017 (in Italian). In."},{"key":"1251_CR30","unstructured":"Ministero della Salute. Ministry of Health. Decree 18 October 2012. Tariffs for acute hospitalization, rehabilitation and post-acute residential hospitalization. Gazzetta Ufficiale, Serie Generale, n. 23, 28 January 2013. Annex 3. Outpatient health care services (in Italian). In."},{"key":"1251_CR31","unstructured":"Ministero della Salute. Ministry of Health. Annual report on hospitalizations. Data obtained from hospital discharge forms 2017. Rome, January 2019 (in Italian). In."},{"key":"1251_CR32","unstructured":"Brouwer W, Rutten F, Koopmanschap M Costing in economic evaluations. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford University Press: Oxford, UK, 2001, pp 68-93."},{"key":"1251_CR33","first-page":"135","volume":"7","author":"G Fattore","year":"2005","unstructured":"Fattore G, Torbica A, Mangone M. Cost analysis of four therapeutic strategies for managing mild and severe COPD patients: an application of the bootstrap method (in Italian). Pharmacoeconomics. 2005;7:135\u201343.","journal-title":"Pharmacoeconomics"},{"key":"1251_CR34","first-page":"39","volume":"11","author":"C Lazzaro","year":"2009","unstructured":"Lazzaro C, Ruffo P, Gozzo M. Cost-effectiveness analysis of budesonide\/formoterol as maintenance and reliever therapy in the management of asthma. Italian evaluation (in Italian). Pharmacoeconomics. 2009;11:39\u201353.","journal-title":"Pharmacoeconomics"},{"key":"1251_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/14737167.2018.1464394","volume":"18","author":"C Lazzaro","year":"2018","unstructured":"Lazzaro C, Barone C, Caprioni F, Cascinu S, Falcone A, Maiello E, et al. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Rev Pharmacoecon Outcomes Res. 2018;18:435\u201346. https:\/\/doi.org\/10.1080\/14737167.2018.1464394. e-pub ahead of print 2018\/04\/12","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1251_CR36","unstructured":"Torrinomedica S.r.l. Ricerca Farmaci [database on the Internet]. Rome: Torrinomedica S.r.l. (in Italian). In, 2019."},{"key":"1251_CR37","unstructured":"Agenzia delle Entrate. Italian Revenue Agency. National tariffs per kilometer for cars and motorbikes set by the Auto club of Italy - Art. 3, paragraph 1, of the legislative decree 2 September 1997, n. 314. Gazzetta Ufficiale, Serie Generale, n. 295, 20 December 2018, ordinary supplement n. 57: 9 (in Italian). In."},{"key":"1251_CR38","unstructured":"Comune di Milano. Municipality of Milan. Authorized parking for non-residents\u2019 car (in Italian). In, 2019."},{"key":"1251_CR39","unstructured":"Banca d\u2019Italia. Bank of Italy. Survey on Household Income and Wealth 2016: Table 13 (in Italian). In."},{"key":"1251_CR40","unstructured":"Istituto Nazionale per la Previdenza Sociale. National Institute for Social Security. Channel Information. Minima daily wages (in Italian). In."},{"key":"1251_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J","volume":"5","author":"J Posnett","year":"1996","unstructured":"Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ. 1996;5:13\u201323. e-pub ahead of print 1996\/01\/01; 10.1002\/(SICI)1099-1050(199601)5:1<13::AID-HEC182>3.0.CO;2-J.","journal-title":"Health Econ"},{"key":"1251_CR42","unstructured":"Sculpher M The role and estimation of productivity costs in economic evaluations. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford University Press: Oxford, UK, 2001, pp 94-112."},{"key":"1251_CR43","unstructured":"Sistema Statistico Nazionale - Istituto Nazionale di Statistica. National Institute for Statistics. Consumer prices index for the whole nation (reference year 2015=100) - monthly data (in Italian). In."},{"key":"1251_CR44","first-page":"83","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore G. for the Italian Association of Health Economics working group. Proposed guide-lines for the economic evaluation of health care programmes in Italy (in Italian). Pharmacoeconomics. 2009;11:83\u201393.","journal-title":"Pharmacoeconomics"},{"key":"1251_CR45","unstructured":"Ministero della Salute. Ministry of Health. Decree 8 February 2013. Criteria for the composition and proper functioning of ethical committees (13A03474). Gazzetta Ufficiale della Repubblica Italiana, Serie Generale, n. 96, 24 April 2013 (in Italian). In."},{"key":"1251_CR46","doi-asserted-by":"crossref","unstructured":"Briggs AH Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A (eds). Economic evaluation in health care: merging theory with practice. Oxford University Press: Oxford, UK, 2001, pp 172-214.","DOI":"10.1093\/oso\/9780192631770.003.0008"},{"key":"1251_CR47","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s10072-014-1632-9","volume":"35","author":"C Lazzaro","year":"2014","unstructured":"Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurol Sci. 2014;35:1023\u201334. https:\/\/doi.org\/10.1007\/s10072-014-1632-9. e-pub ahead of print 2014\/01\/29","journal-title":"Neurol Sci"},{"key":"1251_CR48","unstructured":"Pagano M, Gauvreau K Principles of biostatistics, 2nd edn Duxbury Press: Pacific Grove, USA, 2000."},{"key":"1251_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta3020","volume":"3","author":"AH Briggs","year":"1999","unstructured":"Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess. 1999;3:1\u2013134. e-pub ahead of print 1999\/08\/17","journal-title":"Health Technol Assess"},{"key":"1251_CR50","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0272989X9001000308","volume":"10","author":"WC Black","year":"1990","unstructured":"Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Mak. 1990;10:212\u20134. https:\/\/doi.org\/10.1177\/0272989X9001000308. e-pub ahead of print 1990\/07\/01","journal-title":"Med Decis Mak"},{"key":"1251_CR51","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779\u201387. https:\/\/doi.org\/10.1002\/hec.635. e-pub ahead of print 2001\/12\/18","journal-title":"Health Econ"},{"key":"1251_CR52","doi-asserted-by":"crossref","unstructured":"Glick HA, Doshi JA, Sonnad SA, Polsky D (eds). Economic evaluation in clinical trials. Oxford University Press: Oxford, UK, 2015.","DOI":"10.1093\/med\/9780199685028.001.0001"},{"key":"1251_CR53","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.bbmt.2013.08.005","volume":"19","author":"F Lanza","year":"2013","unstructured":"Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, et al. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transpl. 2013;19:1670\u20136. https:\/\/doi.org\/10.1016\/j.bbmt.2013.08.005. e-pub ahead of print 2013\/08\/31","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.transci.2013.07.025","volume":"49","author":"L Pierelli","year":"2013","unstructured":"Pierelli L, Berto P, Accorsi P, Milone G, Lopatriello S, Aiello A, et al. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societa Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. Transfus Apher Sci. 2013;49:615\u201322. https:\/\/doi.org\/10.1016\/j.transci.2013.07.025. e-pub ahead of print 2013\/08\/27","journal-title":"Transfus Apher Sci"},{"key":"1251_CR55","doi-asserted-by":"publisher","first-page":"102819","DOI":"10.1016\/j.transci.2020.102819","volume":"59","author":"D Laszlo","year":"2020","unstructured":"Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, et al. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Transfus Apher Sci. 2020;59:102819 https:\/\/doi.org\/10.1016\/j.transci.2020.102819. e-pub ahead of print 2020\/06\/06","journal-title":"Transfus Apher Sci"},{"key":"1251_CR56","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.bbmt.2013.05.008","volume":"19","author":"P Shaughnessy","year":"2013","unstructured":"Shaughnessy P, Chao N, Shapiro J, Walters K, McCarty J, Abhyankar S, et al. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transpl. 2013;19:1301\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2013.05.008. e-pub ahead of print 2013\/05\/21","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR57","first-page":"33","volume":"18","author":"SM Kymes","year":"2012","unstructured":"Kymes SM, Pusic I, Lambert DL, Gregory M, Carson KR, DiPersio JF. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care. 2012;18:33\u201341. e-pub ahead of print 2012\/03\/23","journal-title":"Am J Manag Care"},{"key":"1251_CR58","doi-asserted-by":"publisher","first-page":"S248","DOI":"10.1016\/j.bbmt.2011.12.132","volume":"18","author":"HW Tuffaha","year":"2012","unstructured":"Tuffaha HW, Hussein AA, Abdel-Rahman FA. Comparative Cost Utility Analysis of Plerixafor Plus GCSF Versus Cyclophosphamide Plus GCSF as Salvage Mobilization Regimens in Multiple Myeloma Patients. Biol Blood Marrow Transpl. 2012;18:S248 https:\/\/doi.org\/10.1016\/j.bbmt.2011.12.132","journal-title":"Biol Blood Marrow Transpl"},{"key":"1251_CR59","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1056\/NEJM199505253322106","volume":"332","author":"DB Mark","year":"1995","unstructured":"Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N. Engl J Med. 1995;332:1418\u201324. https:\/\/doi.org\/10.1056\/NEJM199505253322106. e-pub ahead of print 1995\/05\/25.","journal-title":"N. Engl J Med"},{"key":"1251_CR60","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","volume":"163","author":"PA Ubel","year":"2003","unstructured":"Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn\u2019t it increase at the rate of inflation? Arch Intern Med. 2003;163:1637\u201341. https:\/\/doi.org\/10.1001\/archinte.163.14.1637. e-pub ahead of print 2003\/07\/30","journal-title":"Arch Intern Med"},{"key":"1251_CR61","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2018. In."},{"key":"1251_CR62","first-page":"31","volume":"1","author":"N Martone","year":"2014","unstructured":"Martone N, Lucioni C, Mazzi S, Fadda V. Cost-effectiveness evaluations of new cancer drugs available on the Italian market (in Italian). Glob Reg Health Tech Assess. 2014;1:31\u201343.","journal-title":"Glob Reg Health Tech Assess"},{"key":"1251_CR63","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41409-020-0940-3","volume":"55","author":"Z Van de Wyngaert","year":"2020","unstructured":"Van de Wyngaert Z, Nerich V, Fouquet G, Chretien ML, Caillot D, Azar N, et al. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. Bone Marrow Transpl. 2020;55:2254\u201360. https:\/\/doi.org\/10.1038\/s41409-020-0940-3. e-pub ahead of print 2020\/05\/25","journal-title":"Bone Marrow Transpl"},{"key":"1251_CR64","doi-asserted-by":"crossref","unstructured":"O\u2019Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ et al. Uncertain judgements: eliciting experts\u2019 probabilities, Wiley: Chichester, UK, 2006.","DOI":"10.1002\/0470033312"},{"key":"1251_CR65","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15:796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012. e-pub ahead of print 2012\/09\/25","journal-title":"Value Health"},{"key":"1251_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014modeling studies. Value Health. 2003;6:9\u201317. https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00234.x. e-pub ahead of print 2003\/01\/22","journal-title":"Value Health"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01251-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01251-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01251-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:24:08Z","timestamp":1724685848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01251-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01251-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"27 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CL has received research grants, speaker or consultancy fees from Boehringer Ingelheim Italia S.p.A., CSL Behring S.p.A., Ferring S.p.A., Ipsen S.p.A., Roche S.p.A., Sanofi S.p.A., Santen GmbH, and Shire Italia S.p.A.; LC has received consultancy fees from Sanofi S.p.A.; FL has received consultancy fees from AbbVie s.r.l. and Sanofi S.p.A.; DL has received consultancy fees from Sanofi S.p.A. and Sandoz S.p.A.; GM declares no disclosures; LP has received consultancy fees from Sanofi S.p.A.; RS has received consultancy fees from Sanofi S.p.A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}